-
River Vision Development Corporation to conduct clinical development under a license from Roche
COPENHAGEN, Denmark I June 11, 2013 I Genmab A/S (GEN.CO) announced today that teprotumumab (RG1507), an antibody developed by Genmab under our collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye disease. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche.
“In drug development, it’s often possible to take what was learned about a product in its initial development and apply it to new indications. We are pleased that River Vision will resume clinical development of teprotumumab for the potential treatment of ophthalmic conditions,” said Jan van de Winkel, Ph.D., Chief Executive Officer.
Under our collaboration with Roche, Genmab will receive milestones as well as royalty payments on successful products.
River Vision Development Corporation is a private company focused on ophthalmology.
Today’s news does not affect Genmab’s financial guidance for 2013. About Teprotumumab
Teprotumumab is a fully human antibody that targets the Insulin-like Growth Factor-1 Receptor (IGF-1R) which is a well validated target. Teprotumumab was previously investigated in various cancer indications.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
SOURCE: Genmab
Post Views: 191
-
River Vision Development Corporation to conduct clinical development under a license from Roche
COPENHAGEN, Denmark I June 11, 2013 I Genmab A/S (GEN.CO) announced today that teprotumumab (RG1507), an antibody developed by Genmab under our collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye disease. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche.
“In drug development, it’s often possible to take what was learned about a product in its initial development and apply it to new indications. We are pleased that River Vision will resume clinical development of teprotumumab for the potential treatment of ophthalmic conditions,” said Jan van de Winkel, Ph.D., Chief Executive Officer.
Under our collaboration with Roche, Genmab will receive milestones as well as royalty payments on successful products.
River Vision Development Corporation is a private company focused on ophthalmology.
Today’s news does not affect Genmab’s financial guidance for 2013. About Teprotumumab
Teprotumumab is a fully human antibody that targets the Insulin-like Growth Factor-1 Receptor (IGF-1R) which is a well validated target. Teprotumumab was previously investigated in various cancer indications.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
SOURCE: Genmab
Post Views: 191
